Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

Osteosarcoma is the most common primary malignant bone tumor, and there are few ideal clinically available drugs. The bromodomain and extraterminal domain (BET) protein is an emerging target for aggressive cancer, but therapies targeting the BET in osteosarcoma have been unsuccessful in clinical tri...

Full description

Bibliographic Details
Main Authors: Yafei Jiang, Gangyang Wang, Haoran Mu, Xiaojun Ma, Zhuoying Wang, Yu Lv, Tao Zhang, Jing Xu, Jinzeng Wang, Yunqi Li, Jing Han, Mengkai Yang, Zongyi Wang, Ke Zeng, Xinmeng Jin, Song Xue, Mingzhu Yin, Wei Sun, Yingqi Hua, Zhengdong Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
osteosarcoma
BRD4
NHWD-870
chemosensitivity
PDX 3
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.642134/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.642134/full

Similar Items